Open AccessA Single Institution's Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma
Author(s) -
Tina Mayer,
Jill Lacy,
Joachim M. Baehring
Publication year - 2008
Publication title -
clinical medicine oncology
Language(s) - English
Resource type - Journals
ISSN - 1177-9314
DOI - 10.4137/cmo.s827
Subject(s) - bevacizumab , medicine , irinotecan , glioma , carboplatin , regimen , chemotherapy , adverse effect , surgery , oncology , colorectal cancer , cancer , cancer research , cisplatin
Bevacizumab and irinotecan may represent one of the most active treatments in progressive malignant glioma. Limited published experience with bevacizumab in patients with CNS tumors raises concerns regarding toxicity, particularly in regards to hemorrhage and thromboembolism.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom